Market Overview:
The global female infertility drugs market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The growth in the market can be attributed to the increasing incidence of female infertility, rising awareness about available treatments, and technological advancements in the field of assisted reproductive technologies (ART). The global female infertility drugs market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into parenteral drugs, oral drugs, and others. Parenteral drugs are further sub-segmented into injectable gonadotropins and hCG preparations. Oral contraceptives are also used for treating female infertility; however, they are not considered as a drug class for this purpose. On the basis of application,the market is segmented into ovarian hyperstimulation syndrome (OHSS), multiple-gestation pregnancies (MGP), multiple-birth infants (MBI), premature labor (PL), low birth weight (35 weeks gestation). Geographically,the global female infertility drugsmarketis dividedinto five regions: North America , Latin America , Europe , Asia Pacific ,and Middle East & Africa .
Product Definition:
Female infertility drugs are medications used to treat female infertility, a condition in which a woman is unable to conceive a child. Female infertility may be caused by problems with the ovaries, such as ovarian cysts or polycystic ovary syndrome (PCOS), blocked fallopian tubes, or problems with the uterus. Female infertility drugs work by helping to improve fertility and increase the chance of pregnancy.
Parenteral:
Parenteral is a drug delivery system used to deliver medications directly into the blood vessels of the body. It is majorly used for delivering drugs and nutrients into the vein of an individual. The parenteral route of drug administration offers several advantages such as it allows for precise dosing, it reduces gastrointestinal irritation caused by oral medications, and it minimizes exposure to harmful intestinal bacteria that can damage the lining of the intestine.
Oral:
Oral is a drug that prevents the release of eggs from the ovary. It works by altering certain chemicals in the brain which eventually leads to changes in the behavior, mood, and sensation of sexual desire in women. The drug also prevents pregnancy if taken within 72 hours of having unsafe sexual contact.
Application Insights:
The risk of cesarean delivery segment dominated the global female infertility drugs market in 2017. This can be attributed to increasing awareness about cesarean deliveries and availability of advanced surgical procedures, such as laparoscopic surgeries. According to a study published by NCBI, around 32% of all C-sections performed are because the baby is in danger inside the uterus. Other factors contributing to this large share include higher incidence of multiple births and premature birth among women aged 35 years and above across the globe.
Ovarian hyperstimulation syndrome (OHSS) is another major application segment for these drugs due to its high prevalence rate globally among women undergoing fertility treatment procedures involving stimulation with hormones or medications administered via an injection into one or both ovaries.
Regional Analysis:
North America dominated the global female infertility drugs market in 2017. This can be attributed to rising awareness about available treatment options, increasing government initiatives and supportive programs, and availability of skilled physicians &rologists. Moreover, high adoption of advanced technology for diagnosis and treatment is also driving the regional market growth. In addition, presence of key players in this region with extensive research on drug development is contributing towards its dominance.
Growth Factors:
- Increasing incidence of female infertility
- Growing awareness about available treatments for female infertility
- Rising demand for assisted reproductive technologies (ART)
- Technological advancements in the field of fertility drugs and treatments
- Availability of government funding and insurance coverage for fertility treatments
Scope Of The Report
Report Attributes
Report Details
Report Title
Female Infertility Drugs Market Research Report
By Type
Parenteral, Oral, Others
By Application
Ovarian Hyperstimulation Syndrome, Multiple-gestation Pregnancies, Multiple-birth Infants, Premature Labor, Low Birth Weight, Risk of Cesarean Delivery
By Companies
Allergan Plc, Ferring BV, Merck KGaA, Novartis AG, Sanofi
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
150
Number of Tables & Figures
105
Customization Available
Yes, the report can be customized as per your need.
Global Female Infertility Drugs Market Report Segments:
The global Female Infertility Drugs market is segmented on the basis of:
Types
Parenteral, Oral, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Ovarian Hyperstimulation Syndrome, Multiple-gestation Pregnancies, Multiple-birth Infants, Premature Labor, Low Birth Weight, Risk of Cesarean Delivery
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Allergan Plc
- Ferring BV
- Merck KGaA
- Novartis AG
- Sanofi
Highlights of The Female Infertility Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Parenteral
- Oral
- Others
- By Application:
- Ovarian Hyperstimulation Syndrome
- Multiple-gestation Pregnancies
- Multiple-birth Infants
- Premature Labor
- Low Birth Weight
- Risk of Cesarean Delivery
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Female Infertility Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Female infertility drugs are medications that help to improve the chances of a woman becoming pregnant. These drugs can be used in combination with other treatments, such as fertility treatments.
Some of the key players operating in the female infertility drugs market are Allergan Plc, Ferring BV, Merck KGaA, Novartis AG, Sanofi.
The female infertility drugs market is expected to register a CAGR of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Female Infertility Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Female Infertility Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Female Infertility Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Female Infertility Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Female Infertility Drugs Market Size & Forecast, 2018-2028
4.5.1 Female Infertility Drugs Market Size and Y-o-Y Growth
4.5.2 Female Infertility Drugs Market Absolute $ Opportunity
Chapter 5 Global Female Infertility Drugs Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Female Infertility Drugs Market Size Forecast by Type
5.2.1 Parenteral
5.2.2 Oral
5.2.3 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Female Infertility Drugs Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Female Infertility Drugs Market Size Forecast by Applications
6.2.1 Ovarian Hyperstimulation Syndrome
6.2.2 Multiple-gestation Pregnancies
6.2.3 Multiple-birth Infants
6.2.4 Premature Labor
6.2.5 Low Birth Weight
6.2.6 Risk of Cesarean Delivery
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Female Infertility Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Female Infertility Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Female Infertility Drugs Analysis and Forecast
9.1 Introduction
9.2 North America Female Infertility Drugs Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Female Infertility Drugs Market Size Forecast by Type
9.6.1 Parenteral
9.6.2 Oral
9.6.3 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Female Infertility Drugs Market Size Forecast by Applications
9.10.1 Ovarian Hyperstimulation Syndrome
9.10.2 Multiple-gestation Pregnancies
9.10.3 Multiple-birth Infants
9.10.4 Premature Labor
9.10.5 Low Birth Weight
9.10.6 Risk of Cesarean Delivery
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Female Infertility Drugs Analysis and Forecast
10.1 Introduction
10.2 Europe Female Infertility Drugs Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Female Infertility Drugs Market Size Forecast by Type
10.6.1 Parenteral
10.6.2 Oral
10.6.3 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Female Infertility Drugs Market Size Forecast by Applications
10.10.1 Ovarian Hyperstimulation Syndrome
10.10.2 Multiple-gestation Pregnancies
10.10.3 Multiple-birth Infants
10.10.4 Premature Labor
10.10.5 Low Birth Weight
10.10.6 Risk of Cesarean Delivery
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Female Infertility Drugs Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Female Infertility Drugs Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Female Infertility Drugs Market Size Forecast by Type
11.6.1 Parenteral
11.6.2 Oral
11.6.3 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Female Infertility Drugs Market Size Forecast by Applications
11.10.1 Ovarian Hyperstimulation Syndrome
11.10.2 Multiple-gestation Pregnancies
11.10.3 Multiple-birth Infants
11.10.4 Premature Labor
11.10.5 Low Birth Weight
11.10.6 Risk of Cesarean Delivery
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Female Infertility Drugs Analysis and Forecast
12.1 Introduction
12.2 Latin America Female Infertility Drugs Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Female Infertility Drugs Market Size Forecast by Type
12.6.1 Parenteral
12.6.2 Oral
12.6.3 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Female Infertility Drugs Market Size Forecast by Applications
12.10.1 Ovarian Hyperstimulation Syndrome
12.10.2 Multiple-gestation Pregnancies
12.10.3 Multiple-birth Infants
12.10.4 Premature Labor
12.10.5 Low Birth Weight
12.10.6 Risk of Cesarean Delivery
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Female Infertility Drugs Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Female Infertility Drugs Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Female Infertility Drugs Market Size Forecast by Type
13.6.1 Parenteral
13.6.2 Oral
13.6.3 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Female Infertility Drugs Market Size Forecast by Applications
13.10.1 Ovarian Hyperstimulation Syndrome
13.10.2 Multiple-gestation Pregnancies
13.10.3 Multiple-birth Infants
13.10.4 Premature Labor
13.10.5 Low Birth Weight
13.10.6 Risk of Cesarean Delivery
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Female Infertility Drugs Market: Competitive Dashboard
14.2 Global Female Infertility Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Allergan Plc
14.3.2 Ferring BV
14.3.3 Merck KGaA
14.3.4 Novartis AG
14.3.5 Sanofi
